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Background.Renaldiseaseiscommonlydescribedasacomplicationofmetabolicsyndrome(MetS)butsomerecentstudiessuggest
that Chronic Kidney disease (CKD) may actually antecede MetS. Few studies have explored the predictive utility of co-clustering
CKDwithMetSforcardiovasculardisease(CVD)mortality.Methods.DatafromanationallyrepresentativesampleofUnitedStates
adults (NHANES) was utilized. A sample of 13115 non-pregnant individuals aged ≥ 35 years, with available follow-up mortality
assessment was selected. Multivariable Cox Proportional hazard regression analysis techniques explored the relationship between
co-clustered CKD, MetS and CVD mortality. Bayesian analysis techniques tested the predictive accuracy for CVD Mortality of
two models using co-clustered MetS and CKD and MetS alone. Results. Co-clustering early and late CKD respectively resulted
in statistically signiﬁcant higher hazard for CVD mortality (HR = 1.80, CI = 1.45–2.23, and HR = 3.23, CI = 2.56–3.70) when
compared with individuals with no MetS and no CKD. A model with early CKD and MetS has a higher predictive accuracy
(72.0% versus 67.6%), area under the ROC (0.74 versus 0.66), and Cohen’s kappa (0.38 versus 0.21) than that with MetS alone.
Conclusion. The study ﬁndings suggest that the co-clustering of early CKD with MetS increases the accuracy of risk prediction for
CVD mortality.
1.Introduction
Cardiovascular disease (CVD) remains the leading cause of
death and disability in the United States, accounting for
approximately 1 of every 2.8 deaths recorded in the United
States [1]. The tendency for the major CVD risk factors
to occur in clusters informed considerable research interest
leading to the description of Metabolic Syndrome (MetS)
[2]. The National Cholesterol Education Program (NCEP)
Adult Treatment Panel (ATP) III accepts the cooccurrence
of abdominal obesity, atherogenic dyslipidemia, elevated
blood pressure, insulin resistance with or without glucose
intolerance, prothrombotic states, and proinﬂammatory
states as MetS [3]. Although the precise pathophysiological
mechanism of MetS is unknown, there is ample evidence of
the association of this syndrome with CVD and CKD.
CKD is the ninth leading cause of death in the United
Stateswithanestimated19millionU.S.adults(6%)reported
to have some form of CKD [4]. The association of several
components of MetS with CKD [5–8] has engendered the
perception of CKD as a long-term complication of MetS.
However, the establishment of hyperinsulinemia and glu-
cose intolerance as the pathophysiological bases for insulin
resistance in patients with renal disease along with the
recent implication of the renin-angiotensin system in local
pancreatic islet structure and function suggests a plausible
common pathophysiological mechanism for MetS and CKD
[9, 10].
CKD is an established independent predictor of CVD
mortality and a long-term complication of several of the
individual components of MetS. However, the value of the
diagnosis of MetS as an independent predictor of CVD
mortality is controversial [2, 11]. A recent review of existing
prospective data concludes that the CVD risk associated with
the diagnosis of MetS varies with the components employed
in the diagnosis of the syndrome and that the diagnosis
of MetS itself only modestly predicts (Relative Risk 1.65–
1.93) CVD mortality [12, 13]. Many of the components
of MetS are also established CVD risk factors and the
clinical challenge has always been the establishment of2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
the additional risk posed by the diagnosis of MetS above
and beyond the sum of the CVD risk factors employed in its
diagnosis.
We hypothesize that the inclusion of indices of CKD in
the diagnostic criteria for MetS will reﬁne its identity as
a clinical entity and improve its predictive value for CVD
mortality. The purpose of our study is to explore the eﬀect of
including indices of CKD as deﬁned by the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDQI) study [14] in the diagnostic criteria for MetS on
the predictive value of the syndrome for CVD mortality in
a nationally representative sample.
2.SubjectsandMethods
This study utilized data from a nationally representative
sample of the civilian, noninstitutionalized US population
collected by the Centers for Disease Control and Prevention
during the third National Health and Nutrition Examination
Surveys (NHANES III) conducted at 89 survey locations
between January 1, 1988, and December 31, 1994. This
survey utilized a complex multistage cluster design and over-
sampled persons 60 years and older, non-Hispanic black
individuals, and Mexican American individuals to enhance
the precision of prevalence estimates in these groups. In-
person interviews were conducted in sampled households,
and all subjects were invited to participate in medical
examinations conducted at a nearby NHANES III mobile
examination center. Interviews consisted of demographic,
socioeconomic, dietary, as well as health-related questions,
andthemobileexaminationcomponentconsistedofmedical
and dental examinations, physiological measurements, and
laboratory tests. The prevalence of common chronic condi-
tions and associated risk factors was also determined during
this survey. Details of the survey design and examination
procedures have been previously published [15, 16]. The
primary study outcome, CVD mortality was recorded from
the NHANES III mortality follow-up data. This mortality
follow-up data relied on a probabilistic match between
NHANES III and National Death Index (National Center
for Health Statistics (NCHS) 2006) death certiﬁcate records
available for a total of 18,149 participants of the total 30,818
(59%) adult participants (those 17 years and older) that
completed the initial interviews and physical examination
and laboratory assessment at a mobile examination center
[17]. Mortality assessments were conducted from the base-
lineinterviewin1988–1994throughtheendofthefollow-up
period in December 31, 2000. These mortality data included
cause speciﬁc mortality and mortality dates. Cause speciﬁc
mortality was coded using the International Classiﬁcation
of Diseases Ninth Revision (ICD-9) Clinical Modiﬁcation
for deaths occurring between 1988 and 1998 and the
International Classiﬁcation of Diseases Tenth Revision for
deaths occurring between 1999 and 2000. We selected the
total sample of individuals with mortality assessment during
the follow-up period (n = 18,149). Of these we excluded
participants who were pregnant and less than 35 years of age
to get a total sample size of 13115 for analysis.
3. Study Variables
3.1. Outcome Variable. CVD mortality was the primary
outcome variable of interest. Using the NHANESIII ICD-9
codes for deaths occurring between 1988 and 1998 and the
ICD-10 Tenth Revision for deaths occurring between 1999
and 2000 we created a dichotomous variable with categories
for CVD mortality and no-CVD mortality [17].
3.2. Primary Predictor Variable. The primary predictor vari-
ablewascocusteredMetSandCKD.Tocomputethisvariable
we ﬁrst deﬁned the individual metabolic risk factors or
conditions consistent with the National Cholesterol Educa-
tion Program (NCEP) Adult Treatment Panel III (ATP III)
classiﬁcationamongthesample[18]:speciﬁcally(a)Elevated
waist circumference: Men ≥ 40inches (102cm) and Women,
≥ 35inches (88cm), (b) Elevated triglycerides: ≥150mg/dL,
(c) Reduced HDL cholesterol: Men ≤ 40mg/dL or Women
≤ 50mg/dL, (d) Elevated blood pressure: ≥130/85 mm Hg,
(e) Elevated fasting glucose: ≥110mg/dL, (f) Prothrombotic
state: ﬁbrinogen >350mg/dL, and (g) Proinﬂammatory
state: C-reactive proteins: > 0.5mg/dL. Then we identiﬁed
study participants meeting a minimum of three of these
criteria and classiﬁed them as having MetS. We also created
a trichotomous CKD variable using the KDQI study clas-
siﬁcation for stages of CKD [19]. Individuals in stages 3–
5 (eGFR of 0–59mL/min/1.73m2) were classiﬁed as having
late CKD; individuals in the stages 1 and 2 (eGFR of 60–
89mL/min/1.73m2 or eGFR of >90mL/min/1.73m2 with
proteinuria) were classiﬁed as having early CKD. All other
individuals were classiﬁed as having normal kidney function.
Finally we created a dummy variable with six categories for
all the possible permutations of renal dysfunction and MetS
from the two variables described earlier. The categories were
as follows: (a) No MetS and No CKD, (b) No MetS and Early
CKD, (c) No MetS and Late CKD, (d) MetS and No CKD, (e)
MetS and Early CKD, and (f) MetS and Late CKD.
3.3. Covariates. Covariates included factors demonstrated
to be associated with CVD mortality and include socio-
demographic, smoking status, history of CVD, and mor-
tality follow-up duration. Speciﬁcally, demographic factors
included gender, age was categorized as <65 years and ≥65
years of age, gender, race, ethnicity, and poverty/income
ratio. Smoking status was categorized as never smoked,
formersmokersandcurrentsmokers.Individualswithaself-
reported history of physician diagnosis of stroke, myocardial
infarction, and congestive heart failure were categorized as
having a history of CVD. The time from baseline assessment,
mortality assessment or death was included in the analysis to
control for any temporal inﬂuences of time on the outcome
of interest (CVD mortality).
4.StatisticalAnalysis
Descriptive analyses of all the variables utilized in the data
analysis were conducted. We explored the distribution of the
variables among categories of CVD and no CVD mortality.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Table 1: Sample weighted distribution of study variables (n = 13115).
Variables %
Race
White 49.9%
African american 24.8%
Hispanic & other 25.4%
Gender
Male 46.7%
Female 53.3%
Age (years)
<65 60.0%
≥65 40.0%
Poverty/income ratio
<1 36.3%
≥1 63.7%
Smoking status
Never smoked 45.4%
Ever-smoker (currently nonsmoker) 31.4%
Current-smoker 23.1%
History of CVD (stroke, MI & congestive heart failure)
No 86.9%
Yes 13.1%
Hypertriglyceridemia
<150mg/dL 59.3%
≥150mg/dL 40.7%
Decreased HDL cholesterol (men ≤ 40mg/dL/women ≤ 50mg/dL)
No 62.0%
Yes 38.0%
Blood pressure (≥130/85mmHg)
<110mmHg systolic & 85mmHg diastolic 36.8%
>130mmHg systolic or >85mmHg diastolic 63.2%
Diabetes (FBS, medications for DM & physician diagnosis)
<110mg/dL 74.9%
>110 25.1%
Central obesity (waist circumference: men ≥ 40 inches/women ≥ 35 inches)
No 49.9%
Yes 50.4%
Proinﬂammatory state (CRP ≥ 3mg/dL)
No 73.0%
Yes 27.0%
Prothrombotic state (ﬁbrinogen ≥ 350mg/dL )
No 71.7%
Yes 28.3%
Metabolic syndrome (meet at criteria for 3 or ATP III criteria)
No 77.9%
Yes 22.1%
Renal dysfunction (eGFR inmL/min/1.73m2 and proteinuria)
0–59 9.5%
60–89 or eGFR ≥90 with proteinuria 43.9%
≥90 with no proteinuria 46.6%4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Continued.
Variables %
Renal dysfunction & metabolic syndrome
No metabolic syndrome and no renal dysfunction 31.9%
No metabolic syndrome and early renal dysfunction 24.4%
No metabolic syndrome and late renal dysfunction 3.6%
Metabolic syndrome and no renal dysfunction 14.7%
Metabolic syndrome and early renal dysfunction 19.4%
Metabolic syndrome and late renal dysfunction 6.0%
CVD speciﬁc mortality
No 88.2%
Yes 11.8%
Interview/exam to mortality follow-up period in months (mean ± std) 96.5 [±33.0]
Sample excludes individuals aged <35 years, pregnant, or have no mortality assessment.
Table 2: Distribution of Independent Variables and Cardiovascular Disease Mortality (n = 13115).
Independent variables No CVD mortality CVD mortality
frequency (%) frequency (%)
Percentage of population 88.2% 11.8
Race
White 84.5% 15.5%
African american 90.7% 9.3%
Hispanic & other 92.9% 7.1
Gender
Male 87.1% 12.9%
Female 89.1% 10.9
Age (years)
<64 97.2% 2.8%
≥65 74.7% 25.3
Poverty/income ratio
<1 84.9% 15.1%
≥1 90.0% 10.0
Smoking status
Never smoked 88.0% 12.0%
Ever-smoker (currently nonsmoker) 85.6% 14.4%
Current smoker 92.0% 8.0
History of CVD (stroke, MI & congestive heart failure)
No 91.3% 8.7%
Yes 67.0% 33.0
Metabolic syndrome (meet at criteria for 3 or ATP III criteria)
No 88.2% 11.8%
Yes 88.2% 11.8
Renal dysfunction (eGFR inmL/min/1.73 m2 and proteinuria)
0–59 95.3% 33.7%
60–89 or eGFR ≥90 with proteinuria 89.8% 11.7%
≥90 with no proteinuria 61.9% 4.5
Renal dysfunction & metabolic syndrome
No metabolic syndrome and no renal dysfunction 96.3% 3.7%
No metabolic syndrome and early renal dysfunction 89.8% 10.2%
No metabolic syndrome and late renal dysfunction 61.9% 38.1%
Metabolic syndrome and no renal dysfunction 93.9% 6.1%
Metabolic syndrome and early renal dysfunction 86.4% 13.6%
Metabolic syndrome and late renal dysfunction 69.0% 31.0%J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
Table 3: Univariate and Multivariable Cox Regression Analysis Cardiovascular Disease Mortality versus Independent Variables (n = 13115).
Univariate analysis Multivariable analysis
OR 95.0% C.I. Sig. OR 95.0% C.I. Sig.
Race
White (ref) 1.00 — 1.00 —
African american 0.57 0.50–0.65 <.001 0.83 0.71–0.98 .02
Hispanic & other 0.42 0.36–0.48 <.001 0.69 0.59–0.82 <.001
Gender (ref)
Female 1.00 — 1.00 —
Male 1.21 1.09–1.33 <.001 1.40 1.23–1.59 <.001
Age (years)
<64 (ref) 1.00 — 1.00 —
≥65 3.42 3.20–3.70 <.001 2.62 2.40–2.85 <.001
Poverty/income ratio
<1 (ref) 1.00 — 1.00 —
>1 0.63 0.57–0.70 <.001 0.73 0.64–0.83 <.001
Smoking status
Never smoked (ref) 1.00 — 1.00 —
Ever-smoker (currently nonsmoker) 1.23 1.10–1.37 <.001 0.97 0.85–1.11 N/S
Current-smoker 0.64 0.55–0.74 <.001 1.07 0.89–1.28 N/S
History of CVD (stroke, MI & congestive heart failure)
No (ref) 1.00 — 1.00 —
Yes 5.10 4.60–5.66 <.001 2.40 2.11–2.72 <.001
Renal dysfunction & metabolic syndrome
No metabolic syndrome and no renal dysfunction (ref) 1.00 — 1.00 —
No metabolic syndrome and early renal dysfunction 3.02 2.45–3.72 <.001 1.69 1.37–2.10 <.001
No metabolic syndrome and late renal dysfunction 15.39 12.16–19.48 <.001 3.92 3.06–5.03 <.001
Metabolic syndrome and no renal dysfunction 1.71 1.31–2.22 — 1.22 0.94–1.60 —
Metabolic syndrome and early renal dysfunction 4.14 3.36–5.09 <.001 1.80 1.45–2.23 <.001
Metabolic syndrome and late renal dysfunction 12.81 10.27–16.00 <.001 3.23 2.56–3.70 <.001
Table 4: Area under the Curve (AUC) for CVD Mortality using unadjusted metabolic syndrome measure compared with cocustered
metabolic syndrome and early stage renal disease.
Area under the ROC Accuracy Cohen’s Kappa Mortality cases/total
Metabolic syndrome 0.66 67.6% 0.21 1551/13115
Metabolic syndrome and early renal dysfunction 0.74 72.0% 0.38 418/5604
Using the Cox proportional hazard model in multiple
survival analysis regression tests and controlling for the
inﬂuence of time to mortality assessment from baseline we
explored the Univariate relationship between the predictor
variables and CVD mortality (including both censored and
event categories). The time to event was considered the
time from the baseline laboratory measures and survey
measurement to the time of mortality assessment or death
of participants. A ﬁnal multivariable survival analysis model
was then created using all the signiﬁcant predictors of
CVD mortality in the univariate models to examine the
inﬂuence of MetS and CKD on CVD mortality. Tests were
conducted to rule out collinearity prior to running the ﬁnal
multivariable regression analysis model including all the
covariates noted above. All data analyses were conducted
using SAS (version 8.0; SAS Institute Inc, Cary, NC) and
SPSS (version 15.0). Statistical hypotheses were tested using
P<.05 as the level of statistical signiﬁcance. Finally we also
utilized the Bayesian analysis technique using the Waikato
Environment for Knowledge Analysis software (Weka 3.0) to
testthepredictiveaccuracyofamodelincludingacocustered
MetS and early CKD variable when compared to a model
including separate MetS and early CKD measures while
adjusting for other predictors of CVD mortality identiﬁed in
the Univariate analysis.
5. Results
5.1. Sample Characteristics. The sociodemographic and clin-
ical characteristics of the study sample are presented in6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 1: Survival function for CVD mortality versus cocustered
metabolic syndrome and renal dysfunction. MetS stands for
metabolic syndrome and CKD stands for chronic kidney disease.
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Figure 2: Bar chart: adjusted hazard ratios for cvd mortality
versus categories of cocustered metabolic syndrome and renal
dysfunction. OR for metabolic syndrome and no renal dysfunction
not signiﬁcant at P <.05.
Table 1. Among the sample about 53% were female and 40%
were aged 65 years or older. About 22% met at least 3 criteria
for MetS. About 9.5% of the sample had eGFR levels below
60mL/min/1.73m2 and 43.9% had eGFR between 60 and
89mL/min/1.73m2 or greater than 90 with some evidence of
proteinuria. The mean mortality follow-up period was about
97 months and CVD speciﬁc mortality among the sample
was about 11.8%.
5.2. Distribution of CVD Mortality. The distribution of CVD
speciﬁc mortality in the sample is presented in Table 2.
Higher mortality rates were observed in individuals who
were male (12.9%), aged greater than 65 years (25.3%), lived
belowthe100%federalpovertyline(15.1%),hadahistoryof
CVD (33.0%), had eGFR below 60mL/min/1.73m2 (33.7%)
or had late stage renal disease without cooccurring MetS
(38.1%) closely followed by individuals with both late stage
renal disease with cooccurring MetS (31.0%).
5.3. Unadjusted Relationship: Cocustered CKD and MetS
versusCVDMortality. UnivariateanalysisusingCoxpropor-
tional hazard analysis demonstrated that individuals aged
≥65 years or older, male, who had a history of CVD, were
white and lived below the 100% federal poverty income
line were more likely to had signiﬁcantly greater hazard
of mortality (Table 3). Using the cocustered CKD and
MetS variables categories, the results demonstrated that in
increasing order, early CKD without MetS (HR = 3.02, CI
= 2.45–3.72), MetS and early CKD (HR = 4.14, CI = 3.36–
5.09), MetS and late CKD (HR = 12.81, CI = 10.27–16.00),
and ﬁnally late CKD without MetS (HR = 15.39, CI = 12.16–
19.48) all had a statistically signiﬁcant higher mortality
hazard when compared to no MetS or CKD. Individuals
with MetS and no CKD did not demonstrate any statistically
signiﬁcant diﬀerence in hazard for CVD mortality when
compared with individuals with no MetS or CKD.
5.4. Adjusted Relationship: Cocustered CKD and MetS versus
CVDMortality. Afteradjustingforotherpotentialpredictors
ofmortalityaCoxproportionalhazardmodelwasdeveloped
to explore the relationship between cocustered CKD and
MetS with CVD mortality. All measures reported previously
in the Univariate analysis model as being signiﬁcantly
associated with CVD mortality remained the same (Table 3).
Using the cocustered CKD and MetS variables categories,
the results demonstrated that in the same increasing order
as observed in the Univariate analysis, early CKD without
MetS (HR = 1.69, CI = 1.37–2.10), MetS and early CKD
(HR = 1.80, CI = 1.45–2.23), MetS and late CKD (HR
= 3.23, CI = 2.56–3.70), and ﬁnally late CKD without
MetS (HR = 3.92, CI = 3.06–5.03) all had a statistically
signiﬁcant higher mortality hazard when compared to no
MetS or CKD. Individuals with MetS and no CKD did
not demonstrate any statistically signiﬁcant diﬀerence in
hazard for CVD mortality when compared with individuals
with no MetS or CKD. Figure 1 demonstrates the adjusted
relative hazard for CVD mortality among the categories of
cocustered CKD and MetS variable. Figure 2 presents a bar
chart displaying the adjusted relative hazard ratios for CVD
mortality among the categories of cocustered CKD and MetS
variable.
5.5. Predictive Accuracy of Models Cocustering Early CKD and
MetS versus MetS Alone for CVD Mortality. The results of
the Bayesian analysis as shown in Table 4 demonstrated that
for CVD mortality a model with cocustering of early CKD
and MetS demonstrated higher predictive accuracy (72.0%
versus 67.6%), area under the ROC (0.74 versus 0.66),
and Cohen’s kappa (0.38 versus 0.21) than that with MetS
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6. Discussion
The poor predictive value of the diagnosis of MetS for CVD
mortality has cast serious doubt on the existence of MetS
as a clinical entity distinct from its diagnostic components.
However, the clustering of metabolic abnormalities that led
to the description of the syndrome is still apparent in clinical
practice. This clustering of metabolic abnormalities more
often than would be predicted by chance alone was the
basis for the description of the syndrome and the suggestion
of a common etiology for its components. The initial
association of the syndrome with glucose intolerance and
hyperinsulinemia led to the suggestion of Insulin resistance
as the probable common pathophysiological basis for the
syndrome [20–22]. However, subsequent conﬂicting series
of studies led the National Cholesterol Education Program
(NCEP) Adult Treatment Panel (ATP) III to conclude that
the relationship between insulin resistance and MetS is not
well established [3].
The emerging role of vitamin D as a modulator of both
insulin resistance and the renin-angiotensin system [23]
and the recent implication of the renin-angiotensin system
in local pancreatic islet structure and function suggest a
broader base for a probable common etiology for MetS
than previously anticipated. The traditional association of
CKD with several components of MetS may have led to
the exclusion of CKD as a component of MetS and misled
the search eﬀort for a common pathophysiological basis for
the components of the syndrome. It is in the light of this
emerging body of evidence that we evaluate the eﬀect of
including early CKD in the diagnostic criteria for MetS on
its predictive value for CVD mortality using a nationally
representative sample.
The preponderance of participants with early CKD in
the analysis sample makes it suitable for the isolation of
the inﬂuence of early CKD on the predictive value of MetS
for CVD mortality. The association of CKD with CVD
mortality in this study is consistent with the existing body
of evidence and highlights the signiﬁcance of CKD as an
independent risk factor for CVD mortality. Even in the early
stages CKD carries a signiﬁcant risk for CVD mortality
(OR 1.69; CI 1.37–2.10) (Table 3). In the absence of early
CKD, MetS carries no signiﬁcant risk for mortality in this
study. However, early CKD becomes more hazardous with
a hazard ratio of 1.8 versus 1.69 for CVD mortality in the
presence of MetS (Figure 2). The greater hazard of early
CKD in the presence of MetS is associated with a slight but
similar reduction in survival among the aﬀected participants
(Figure 1). The apparent lack of a signiﬁcant association
between MetS and CVD mortality is consistent with the
results of several previous studies but the increase in the
hazard ratio for CVD mortality associated with early CKD
in the presence of MetS gives credence to a potential renal
contribution to the pathogenesis and perhaps mortality of
MetS.
The primary purpose of this study was to explore
the implication of including indices of early CKD in the
diagnostic criteria of MetS for the predictive value of the
syndrome for CVD mortality. The results of this study
suggest a broader base for a common etiology for MetS and
support the ﬁnding of a potential renal contribution to the
etiology of the syndrome. The results of this study represent
an analysis of a nationally representative sample of 13,115
participantswithameanmortalityfollow-upperiodofabout
97 months and CVD speciﬁc mortality of 11.8%.
However, the mortality follow-up data employed in this
study relied on a probabilistic match between NHANES
III and National Death Index (National Center for Health
Statistics (NCHS) 2006) death certiﬁcate records available
and inaccurate matches for CVD speciﬁc mortality may
potentially confound the study ﬁndings, particularly since
a few studies suggest that appropriately identifying CVD-
speciﬁc mortality may inadvertently result in misclassiﬁca-
tion of cause speciﬁc mortality [24]. Also given the cross
sectional nature of risk measures utilized in our study the
impact of other confounding events post assessment may
impact our ﬁnding and inﬂuence the attribution of CVD
mortality to our study risk measures.
Overall the study ﬁndings that early CKD may cocuster
with MetS to result in an increased mortality burden should
inform more studies to explore the temporal relationship
between the pathogenesis of CKD and MetS.
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